ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1467

Association of Gastroesophageal Factors and Progression of Interstitial Lung Disease in the Canadian Scleroderma Research Group, a Large, Multicenter Database

Xuli Jerry Zhang1, Ashley Bonner2, Murray Baron3, Marie Hudson4, Janet E. Pope5 and Canadian Scleroderma Research Group6, 1Western University, London, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 4Jewish General Hospital, McGill University, Montreal, QC, Canada, 5Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 6Montreal, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is a leading contributor to mortality in SSc patients. Once lung fibrosis occurs, lung function disease course may become stable or progressively decline. While some demographic and SSc-related factors have been associated with development of ILD, little is known about what contributes to progression. We studied the clinical manifestations of SSc-gastroesophageal (GE) involvement in relation to ILD status to determine associations between GE involvement and ILD progression in SSc.  Our objective was to determine if GE reflux and dysphagia are associated with progressive ILD as measured by PFTs over three years.

Methods: Canadian Scleroderma Research Group (CSRG), a multi-center database of adult SSc patients, annually evaluates and collects patient information including demographics, skin manifestations, internal organ involvement and function assessment data. Using indicators of GE involvement and annual pulmonary function test results from the CSRG database, comparisons were made between no ILD, stable ILD and progressive ILD groups based on FVC% predicted. Univariate and multivariate analysis were used to determine association between GE factors and ILD development and progression.

Results: The study included data of 1043 SSc patients with mean age of 55.7 years and mean disease duration of 10.8 years. Among the variables of interest, physician indicators such as esophageal dysmotility (P=0.009) and post-esophageal dilatation (P=0.041) along with patient indicators such as difficulty swallowing (P=0.016), waking up choking (P=0.026) appeared to significantly increase risk of developing ILD. In comparing progressive vs. stable ILD patients, early satiety (p=0.018) a combination term composed of post-dilatation*choking (p=0.042) increased risk of ILD progression.

Conclusion: Indicators of esophageal dysmotility and GERD studied appear to be associated with ILD in SSc, with some factors specifically related to progressive ILD. Further, the strong association of an interaction term of both dysmotility and GERD with progressive ILD illustrates a potential dose-response phenomenon. These results hold important implications for management of ILD in SSc.

Table 1. Logistic regression models for dysphagia and GERD indicators. Results are OR (P-value). GI variable of interest is what each model studied (listed under each Model). Covariates with P<0.1 from univariate logistic regression were included for each comparison. Odds ratio are indicated as OR (p-value). P<0.05 was considered to be significant. (-) indicates that multivariate analysis could not be performed. Pulmonary arterial hypertension (PAH)=physician answering yes to ‘Has the patient ever had pulmonary hypertension? * indicates interaction term between indicated variables.

 

Moderate/Severe ILD vs. No/mild ILD

Single Effects

 

Interaction Effects

 

Model 1

Model 2

Model 3

Model 4

Model 5

Model 6

Model 7

 

Model 8

Model 9

COVARIATES

Dilatation

Dysmotility

Difficulty Swallowing

Choking

Heartburn

Food/ Acid

Early Satiety

 

Dilatation*

Difficulty Swallowing

Dilatation* Choking

ESR

1.014 (.007)

1.016 (.003)

1.019 (.001)

1.007 (.002)

1.019 (.001)

1.019 (.001)

1.019 (.001)

 

1.019 (.001)

1.018 (.002)

ACA

0.497 (.024)

.500 (.026)

0.470 (.017)

0.480 (.020)

0.505 (.029)

.501 (.028)

.485 (.022)

 

0.448 (.012)

0.462 (.015)

Digital Ulcers

1.925 (.016)

1.843 (.025)

1.649 (.072)

1.716 (.051)

1.742 (.044)

1.759 (0.41)

1.792 (.035)

 

1.649 (.072)

1.667 (.067)

Pulmonary Hypertension

2.317 (.005)

2.420 (.003)

2.436 (.004)

2.704 (.001)

2.602 (.002)

2.538 (.002)

2.452 (.003)

 

2.509 (.003)

2.658 (.002)

 

 

 

 

 

 

 

 

 

 

 

GI variable of interest

1.937 (.041)

6.742 (.009)

1.993 (.016)

1.962 (.026)

1.334 (.327)

1.133 (.652)

1.538 (.119)

 

1.871 (.476)

0.607 (.468)

 

 

 

 

 

 

 

 

 

 

 

Progressive vs. Stable

Single Effects

 

Interaction Effects

 

Model 1

Model 2

Model 3

Model 4

Model 5

Model 6

Model 7

 

Model 8

Model 9

COVARIATES

Dilatation

Dysmotility

Difficulty Swallowing

Choking

Heartburn

Food/Acid

Early Satiety

 

Dilatation* Difficulty Swallowing

Dilatation* Choking

Age

1.066 (.014)

1.068 (.0110

1.069 (.013)

1.067 (.013)

1.062 (.021)

1.071 (.011)

1.072 (.010)

 

1.069 (.012)

1.075 (.011)

Telangiectasia

0.124 (.036)

.126 (.033)

0.122 (.028)

0.127 (0.34)

0.138 (.044)

.124 (.040)

.073 (0.17)

 

0.142 (.052)

0.095 (.028)

 

 

 

 

 

 

 

 

 

 

 

GI variable of interest

2.150 (.263)

–

2.045 (.248)

1.325 (.653)

2.680 (.098)

3.009 (.072)

4.573 (.018)

 

0.367 (.677)

29.075 (.042)

 

 


Disclosure:

X. J. Zhang,
None;

A. Bonner,
None;

M. Baron,
None;

M. Hudson,
None;

J. E. Pope,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-gastroesophageal-factors-and-progression-of-interstitial-lung-disease-in-the-canadian-scleroderma-research-group-a-large-multicenter-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology